Induction therapy followed by surgical resection in Stage-III thimic epithelial tumors: Long-term results from a multicentre analysis of 108 cases

Giuseppe Cardillo, Marco Lucchi, Giuseppe Marulli, Maurizio Infante, Giovanni Leuzzi, Alfredo Mussi, Francesco Carleo, Francesco Facciolo, E. Voulaz, Federico Rea, Cristian Rapicetta, Filippo Lococo

Research output: Contribution to journalArticle

Abstract

Introduction: So far no specific oncological strategies have been validated for locally-advanced epithelial thymic tumors (TETs). We herein report the long-term results of a large multicentric experience adopting a multimodal treatment. Methods: From 01/1990 to 12/2010, the clinical data of 108 Masaoka Stage-III TETs patients surgically treated after induction therapy (IT) were retrospectively reviewed. Different IT-regimens were administered: ADOC (32 pts); PAC (38 pts); CEE (38 pts). Radiotherapy was concurrently used in 5 patients only. The end-points of the study were the evaluation of: (1) resectability; (2) overall long-term survival (LTS) and disease-free survival (DFS); and (3) independent prognostic factors. The Mann-Whitney and Fisher's exact tests were applied to test the associations. Survival analysis was performed by the Kaplan-Meier method and log-rank test. Results: Mean age and male/female ratio were 51 ± 13 years and 61/47, respectively. World Health Organization (WHO) histotype was: A in 6 pts (5.6%), AB in 18 (16.7%), B1 in 15 (13.9%), B2 in 26 (24.1%), B3 in 23 (21.3%), and thymic carcinoma in 20 (18.5%). Thirty-day mortality was 1.8%. A total of 81 (75%) had R0-resection, 11 (10.2%) R1 and 16 (14.8%) R2-resection. Adjuvant therapy was performed in 71 patients. During the follow-up a relapse of disease was observed in 38 pts(35.2%). Five-years DFS and LTS were 69.3% and 79.3%, respectively. At univariate analysis, WHO-type B3/C ("high-risk") TETs (p = 0.001) and recurrence of disease (p = 0.02) were predictors of poor LTS while only a slight correlation was found for R-status and "CHT-regimen type" (p = 0.097 and p = 0.067, respectively). At multivariate analysis WHO "high-risk" TETs (H.R.5.73;C.I.:1.77-18.57) and ADOC-regimen (H.R.2.84;C.I.:1.37-5.86) were independent predictors of poor survival. Conclusions: A multimodal treatment for Stage-III thymic tumors may achieve a rewarding survival. WHO-Histology seems to be the most important prognostic factor.

Original languageEnglish
Pages (from-to)88-94
Number of pages7
JournalLung Cancer
Volume93
DOIs
Publication statusPublished - Mar 1 2016

Fingerprint

Survival
Combined Modality Therapy
Neoplasms
Disease-Free Survival
Thymus Neoplasms
Therapeutics
Recurrence
Thymoma
Survival Analysis
Histology
Radiotherapy
Multivariate Analysis
Mortality

Keywords

  • Advanced thymic tumors
  • Induction therapy
  • Multimodality treatment
  • Thymic tumors

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Induction therapy followed by surgical resection in Stage-III thimic epithelial tumors : Long-term results from a multicentre analysis of 108 cases. / Cardillo, Giuseppe; Lucchi, Marco; Marulli, Giuseppe; Infante, Maurizio; Leuzzi, Giovanni; Mussi, Alfredo; Carleo, Francesco; Facciolo, Francesco; Voulaz, E.; Rea, Federico; Rapicetta, Cristian; Lococo, Filippo.

In: Lung Cancer, Vol. 93, 01.03.2016, p. 88-94.

Research output: Contribution to journalArticle

Cardillo, Giuseppe ; Lucchi, Marco ; Marulli, Giuseppe ; Infante, Maurizio ; Leuzzi, Giovanni ; Mussi, Alfredo ; Carleo, Francesco ; Facciolo, Francesco ; Voulaz, E. ; Rea, Federico ; Rapicetta, Cristian ; Lococo, Filippo. / Induction therapy followed by surgical resection in Stage-III thimic epithelial tumors : Long-term results from a multicentre analysis of 108 cases. In: Lung Cancer. 2016 ; Vol. 93. pp. 88-94.
@article{ebbf1cfacae54dd69599807e6eb95eb0,
title = "Induction therapy followed by surgical resection in Stage-III thimic epithelial tumors: Long-term results from a multicentre analysis of 108 cases",
abstract = "Introduction: So far no specific oncological strategies have been validated for locally-advanced epithelial thymic tumors (TETs). We herein report the long-term results of a large multicentric experience adopting a multimodal treatment. Methods: From 01/1990 to 12/2010, the clinical data of 108 Masaoka Stage-III TETs patients surgically treated after induction therapy (IT) were retrospectively reviewed. Different IT-regimens were administered: ADOC (32 pts); PAC (38 pts); CEE (38 pts). Radiotherapy was concurrently used in 5 patients only. The end-points of the study were the evaluation of: (1) resectability; (2) overall long-term survival (LTS) and disease-free survival (DFS); and (3) independent prognostic factors. The Mann-Whitney and Fisher's exact tests were applied to test the associations. Survival analysis was performed by the Kaplan-Meier method and log-rank test. Results: Mean age and male/female ratio were 51 ± 13 years and 61/47, respectively. World Health Organization (WHO) histotype was: A in 6 pts (5.6{\%}), AB in 18 (16.7{\%}), B1 in 15 (13.9{\%}), B2 in 26 (24.1{\%}), B3 in 23 (21.3{\%}), and thymic carcinoma in 20 (18.5{\%}). Thirty-day mortality was 1.8{\%}. A total of 81 (75{\%}) had R0-resection, 11 (10.2{\%}) R1 and 16 (14.8{\%}) R2-resection. Adjuvant therapy was performed in 71 patients. During the follow-up a relapse of disease was observed in 38 pts(35.2{\%}). Five-years DFS and LTS were 69.3{\%} and 79.3{\%}, respectively. At univariate analysis, WHO-type B3/C ({"}high-risk{"}) TETs (p = 0.001) and recurrence of disease (p = 0.02) were predictors of poor LTS while only a slight correlation was found for R-status and {"}CHT-regimen type{"} (p = 0.097 and p = 0.067, respectively). At multivariate analysis WHO {"}high-risk{"} TETs (H.R.5.73;C.I.:1.77-18.57) and ADOC-regimen (H.R.2.84;C.I.:1.37-5.86) were independent predictors of poor survival. Conclusions: A multimodal treatment for Stage-III thymic tumors may achieve a rewarding survival. WHO-Histology seems to be the most important prognostic factor.",
keywords = "Advanced thymic tumors, Induction therapy, Multimodality treatment, Thymic tumors",
author = "Giuseppe Cardillo and Marco Lucchi and Giuseppe Marulli and Maurizio Infante and Giovanni Leuzzi and Alfredo Mussi and Francesco Carleo and Francesco Facciolo and E. Voulaz and Federico Rea and Cristian Rapicetta and Filippo Lococo",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.lungcan.2016.01.008",
language = "English",
volume = "93",
pages = "88--94",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Induction therapy followed by surgical resection in Stage-III thimic epithelial tumors

T2 - Long-term results from a multicentre analysis of 108 cases

AU - Cardillo, Giuseppe

AU - Lucchi, Marco

AU - Marulli, Giuseppe

AU - Infante, Maurizio

AU - Leuzzi, Giovanni

AU - Mussi, Alfredo

AU - Carleo, Francesco

AU - Facciolo, Francesco

AU - Voulaz, E.

AU - Rea, Federico

AU - Rapicetta, Cristian

AU - Lococo, Filippo

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Introduction: So far no specific oncological strategies have been validated for locally-advanced epithelial thymic tumors (TETs). We herein report the long-term results of a large multicentric experience adopting a multimodal treatment. Methods: From 01/1990 to 12/2010, the clinical data of 108 Masaoka Stage-III TETs patients surgically treated after induction therapy (IT) were retrospectively reviewed. Different IT-regimens were administered: ADOC (32 pts); PAC (38 pts); CEE (38 pts). Radiotherapy was concurrently used in 5 patients only. The end-points of the study were the evaluation of: (1) resectability; (2) overall long-term survival (LTS) and disease-free survival (DFS); and (3) independent prognostic factors. The Mann-Whitney and Fisher's exact tests were applied to test the associations. Survival analysis was performed by the Kaplan-Meier method and log-rank test. Results: Mean age and male/female ratio were 51 ± 13 years and 61/47, respectively. World Health Organization (WHO) histotype was: A in 6 pts (5.6%), AB in 18 (16.7%), B1 in 15 (13.9%), B2 in 26 (24.1%), B3 in 23 (21.3%), and thymic carcinoma in 20 (18.5%). Thirty-day mortality was 1.8%. A total of 81 (75%) had R0-resection, 11 (10.2%) R1 and 16 (14.8%) R2-resection. Adjuvant therapy was performed in 71 patients. During the follow-up a relapse of disease was observed in 38 pts(35.2%). Five-years DFS and LTS were 69.3% and 79.3%, respectively. At univariate analysis, WHO-type B3/C ("high-risk") TETs (p = 0.001) and recurrence of disease (p = 0.02) were predictors of poor LTS while only a slight correlation was found for R-status and "CHT-regimen type" (p = 0.097 and p = 0.067, respectively). At multivariate analysis WHO "high-risk" TETs (H.R.5.73;C.I.:1.77-18.57) and ADOC-regimen (H.R.2.84;C.I.:1.37-5.86) were independent predictors of poor survival. Conclusions: A multimodal treatment for Stage-III thymic tumors may achieve a rewarding survival. WHO-Histology seems to be the most important prognostic factor.

AB - Introduction: So far no specific oncological strategies have been validated for locally-advanced epithelial thymic tumors (TETs). We herein report the long-term results of a large multicentric experience adopting a multimodal treatment. Methods: From 01/1990 to 12/2010, the clinical data of 108 Masaoka Stage-III TETs patients surgically treated after induction therapy (IT) were retrospectively reviewed. Different IT-regimens were administered: ADOC (32 pts); PAC (38 pts); CEE (38 pts). Radiotherapy was concurrently used in 5 patients only. The end-points of the study were the evaluation of: (1) resectability; (2) overall long-term survival (LTS) and disease-free survival (DFS); and (3) independent prognostic factors. The Mann-Whitney and Fisher's exact tests were applied to test the associations. Survival analysis was performed by the Kaplan-Meier method and log-rank test. Results: Mean age and male/female ratio were 51 ± 13 years and 61/47, respectively. World Health Organization (WHO) histotype was: A in 6 pts (5.6%), AB in 18 (16.7%), B1 in 15 (13.9%), B2 in 26 (24.1%), B3 in 23 (21.3%), and thymic carcinoma in 20 (18.5%). Thirty-day mortality was 1.8%. A total of 81 (75%) had R0-resection, 11 (10.2%) R1 and 16 (14.8%) R2-resection. Adjuvant therapy was performed in 71 patients. During the follow-up a relapse of disease was observed in 38 pts(35.2%). Five-years DFS and LTS were 69.3% and 79.3%, respectively. At univariate analysis, WHO-type B3/C ("high-risk") TETs (p = 0.001) and recurrence of disease (p = 0.02) were predictors of poor LTS while only a slight correlation was found for R-status and "CHT-regimen type" (p = 0.097 and p = 0.067, respectively). At multivariate analysis WHO "high-risk" TETs (H.R.5.73;C.I.:1.77-18.57) and ADOC-regimen (H.R.2.84;C.I.:1.37-5.86) were independent predictors of poor survival. Conclusions: A multimodal treatment for Stage-III thymic tumors may achieve a rewarding survival. WHO-Histology seems to be the most important prognostic factor.

KW - Advanced thymic tumors

KW - Induction therapy

KW - Multimodality treatment

KW - Thymic tumors

UR - http://www.scopus.com/inward/record.url?scp=84959422632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959422632&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2016.01.008

DO - 10.1016/j.lungcan.2016.01.008

M3 - Article

VL - 93

SP - 88

EP - 94

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

ER -